Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| SRDA19-0411 | Other Grant/Funding Number | Slovak Research and Development Agency |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Comenius University | OTHER |
Not provided
Not provided
Not provided
Not provided
Regular exercise is effective in prevention & treatment of chronic diseases. Exercise can reduce late toxicity of chemotherapy, commonly found in cancer survivors, which is yet to be translated into clinical practice.
Mechanisms of exercise benefits in oncologic patients are far from being elucidated, and include increase in muscle mass, reduction of fat mass, systemic inflammation and cardiometabolic risk. Synchronization of exercise adaptive response is, to an extent, mediated by bioactive molecules released from muscle, with anti-inflammatory & tumor-suppressing properties. Muscle satellite cells are a source of regeneration, muscle structural integrity & functional capacity. Phenotypes of muscle cells, such as secretory profile, lipid & glucose metabolism, mirror clinical phenotypes of the donor. Importantly, muscle cells' metabolism in vitro can be modulated by 8-12 week training in vivo. Epigenetic mechanisms regulating muscle & systemic metabolism in cancer survivors are not yet understood.
Aims:
(iii) on metabolic characteristics of primary skeletal muscle cells;
The generated results will enable us (i) to gain a better insight into pathomechanisms of muscle-associated chemotherapy-induced late toxicity and the role of skeletal muscle & systemic mediators in the exercise-induced health benefits in TGCC survivors; and (ii) to validate the effectiveness of the individually-tailored exercise intervention in reducing chemotherapy-related toxicity in patients with TGCC, with the aim to transfer this knowledge into clinical practice.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| TGCT patients - exercise | Experimental | TGCT survivors, men, 25-55 yrs old, 3 and more years after successful treatment of TGCT, with the capacity to undergo aerobic-strength intervention assessed by cardiologist |
|
| TGCT patients - nonexercising controls | No Intervention | TGCT survivors, men, 25-55 yrs old, 3 and more years after successful treatment of TGCT, with the capacity to undergo aerobic-strength intervention assessed by cardiologist |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| aerobic-strength exercise intervention (6-months) | Behavioral | 6 month supervised exercise intervention in TGCT survivors (1 hour sessions 3 x per week), |
|
| Measure | Description | Time Frame |
|---|---|---|
| change in the glucose tolerance | change in glucose tolerance (as measured by oral glucose tolerance test) | parameter will be measured before and after 6 month intervention |
| change in resting energy expenditiure and metabolic substrate preference | change in resting energy expenditure calculated by Weir equation from VO2 and metabolic substrate preference RQ VCO2/VO2 (as measured by indirect calorimetry) | parameters will be measured twice before and after 6 month intervention |
| change anthropometric parameters of obesity | BMI (kg.m-2) , fat mass (% electric bioimpedance), lean body mass (% electric bioimpedance), visceral adiposity (%, elecgtric bioimpedance) | parameters will be measured twice before and after 6 month intervention |
| change physical fitness | VO2max (mlO2 per kg BW min) as measured by bicycle spiroergometry | parameter will be measured twice before and after 6 month intervention |
| Measure | Description | Time Frame |
|---|---|---|
| change in quality of life for cancer patients | validated questionnaire | measured twice before and after 6 month intervention |
| change in muscle strength | dynamometry |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Barbara Ukropcova, MD, PhD, Prof | Biomedical Research Center, Slovak Acad Sci | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| National Cancer Institute | Bratislava | Please Select | 800 00 | Slovakia | ||
| Biomedical Research Center Slovak Academy of Sciences |
we will share IPD upon reasonable request
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C563236 | Testicular Germ Cell Tumor |
Not provided
Not provided
Not provided
controled trial with exercise intervention
Not provided
Not provided
lab technicians and statistician are blinded.
| measured twice before and after 6 month intervention |
| change in cognitive functions | standardised cognitive test Cogstate | measured twice before and after 6 month intervention |
| Bratislava |
| Please Select |
| 84505 |
| Slovakia |